POS1342 depletion of KLRG1+ T CELLS in a first-in-human clinical trial of ABC008 in Inclusion Body Myositis (IBM)

Goel, N., Needham, M., Soler-Ferran, D., Cotreau, M.M., Escobar, J. and Greenberg, S. (2022) POS1342 depletion of KLRG1+ T CELLS in a first-in-human clinical trial of ABC008 in Inclusion Body Myositis (IBM). Annals of the Rheumatic Diseases, 81 (Suppl. 1). 1008.3-1009.

Abstract

Background Inclusion body myositis (IBM), a relentlessly progressive autoimmune skeletal muscle disease, has no effective available pharmacological therapy. A prominent feature of IBM on microscopy is highly differentiated effector CD8+ cytotoxic T (Tc) cells invading non-necrotic myofibers [1]. These Tc cells, known to be relatively resistant to apoptosis, express markers including killer cell lectin-like receptor G1 (KLRG1) [2]. ABC008, a first-in-class humanized, afucosylated monoclonal antibody (mAb) specific for KLRG1, selectively depletes these highly differentiated Tc cells while sparing other blood cell populations, e.g., naïve, central memory, and regulatory T cells and B cells. ABC008 has been designed to treat diseases mediated by these Tc cells, including IBM and T-cell large granular lymphocytic leukemia (T-LGLL). IBM and rheumatoid arthritis overlap clinically with T-LGLL and share similar expansions of large granular lymphocytes (LGLs), which also express KLRG1. We report here our preliminary data from our ongoing trial of ABC008 in IBM (NCT04659031)...

Item Type:	Journal Article
Murdoch Affiliation(s):	Centre for Molecular Medicine and Innovative Therapeutics
Publisher:	BMJ Publishing Group
Copyright:	© 2022 BMJ Publishing Group Ltd & European Alliance of Associations for Rheumatism.
URI:	http://researchrepository.murdoch.edu.au/id/eprint/66502

Item Control Page